My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

BioCryst Pharmaceuticals, Inc. - Common Stock (NQ:BCRX)

7.570 -0.010 (-0.13%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 12, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioCryst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

BioCryst Continues To Develop A Strong Pipeline ↗

March 15, 2022

Investing in biotech stocks often comes with huge risks and rewards, as a company is dependent on its pipeline and royalty payments.

Via Talk Markets

BioCryst's Orladeyo Shows Long Term Benefit With Sustained Reductions in Attack Rates ↗

February 24, 2022

BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) announced new long-term efficacy and safety data from the APeX-2 trial evaluating Orladeyo (berotralstat) for the...

Via Benzinga

Recap: BioCryst Pharmaceuticals Q4 Earnings ↗

February 23, 2022

BioCryst Pharmaceuticals (NASDAQ:BCRX) reported its Q4 earnings results on Wednesday, February 23, 2022 at 07:00 AM. Here's what investors need to know about the...

Via Benzinga

BioCryst Hit 15-Year Highs But What's In Store Tomorrow For Earnings? ↗

February 22, 2022

By StoryTrading BioCryst’s (NASDAQ: BCRX) stock price hit 15-year highs since our article was published on Benzinga earlier this month, but with the oral prophylactic...

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

February 18, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Can Recent Catalysts Breakout BioCryst To New Highs? ↗

February 09, 2022

In today’s volatile markets, finding a biotech stock that isn’t purely speculative can be challenging, and yet BCRX may have what it takes.

Via Talk Markets

BioCryst Is On Fire: What Do Options Traders Expect Next? ↗

January 12, 2022

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) sur...

Via Benzinga

Analyzing BioCryst Pharmaceuticals's Unusual Options Activity ↗

August 11, 2021

BioCryst Pharmaceuticals (NASDAQ:BCRX) shares experienced...

Via Benzinga

Is BioCryst (BCRX) Ready to Breakout to New Highs on Recent Catalysts? ↗

February 09, 2022

By Ben Rabizadeh – Fundamentals well positioned with $1B peak sales forecast for Orladeyo and $300M influx of cash from royalty deals – Potential catalysts: update on Orladeyo sales with Q4 results on...

Via Benzinga

If You Invested $1000 In This Stock 10 Years Ago, Here's How Much You Would Have Today ↗

January 12, 2022

BioCryst Pharmaceuticals (NASDAQ:BCRX) has outperformed the market over the past 10 years by 5.6% on an annualized basis. Buying $1,000 In BCRX: 10 years ago, an investor could...

Via Benzinga

60 Biggest Movers From Yesterday ↗

January 11, 2022

Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares surged 57.1% to close at $5.39 on Monday. Zynga Inc. (NASDAQ: ZNGA) rose 40.7% to settle at $8.44 after the company...

Via Benzinga

Biotech Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer ↗

January 10, 2022

Pfizer and Bayer inked deals with several companies in gene-editing.

Via Investor's Business Daily

45 Stocks Moving In Monday's Mid-Day Session ↗

January 10, 2022

Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares climbed 71.5% to $5.88. Zynga Inc. (NASDAQ: ZNGA) gained 45.7% to $8.74 after the company announced it will be acquired...

Via Benzinga

3 Stocks Insiders Are Buying ↗

November 26, 2021

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, t...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 10, 2021 ↗

December 10, 2021

Upgrades According to JP Morgan, the prior rating for Arconic Corp (NYSE:

Via Benzinga

BioCryst Shares Gain As Royalty Pharma Buys Additional Interests In BCX9930, Orladeyo ↗

November 22, 2021

Royalty Pharma plc (NASDAQ: RPRX) and OMERS Capital Markets have announced transactions worth $350 million in new funding in BioCryst Pharmaceuticals...

Via Benzinga

7 Top Growth Stocks to Buy as We Step Into November ↗

November 12, 2021

Here are seven top growth stocks investors may want to consider when looking at options in this hyper-growth market right now.

Via InvestorPlace

86 Biggest Movers From Yesterday ↗

November 04, 2021

Gainers FAT Brands Inc. (NASDAQ: FATBB) shares gained 99.2% to settle at $15.44. FAT Brands recently announced plans to acquire Fazoli’s Restaurant Chain for $130 million....

Via Benzinga

BioCryst Pharmaceuticals (BCRX) Q3 2021 Earnings Call Transcript ↗

November 03, 2021

BCRX earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

Here's Why BioCryst Pharmaceuticals Stock Is Losing Ground Today ↗

November 03, 2021

The biotech's third quarter was a good one, once you look past the top-line numbers.

Via The Motley Fool

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

November 03, 2021

Gainers iRhythm Technologies (NASDAQ:IRTC) stock moved upwards by 52.78% to $117.34 during Wednesday's regular session. iRhythm Technologies's stock is trading at...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 03, 2021

Gainers Glaukos (NYSE:GKOS) stock increased by 25.55% to $56.58 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.6 billion...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

October 20, 2021

Gainers Tenet Healthcare (NYSE:THC) stock r...

Via Benzinga

2 Super-Charged Growth Stocks to Buy Now ↗

October 13, 2021

These two small drugmakers are poised for a long-winded growth spurt.

Via The Motley Fool

NICE Recommends BioCryst's Hereditary Angioedema Med ↗

September 16, 2021

The U.K.'s National Institute for Health and Care Excellence (NICE) has recommended BioCryst Pharmaceuticals Inc's (NASDAQ: BCRX) Orladeyo (berotralstat)...

Via Benzinga

US Government Exercises Option To Buy Additional Doses Of BioCryst's Flu Med ↗

September 01, 2021

The U.S. Department of Health and Human Services (HHS) has exercised its option to purchase an additional 10,000 doses of BioCryst Pharmaceuticals Inc's (...

Via Benzinga

The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO ↗

August 26, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 25) Abbvie Inc. (NYSE: ABBV)...

Via Benzinga

Analyzing BioCryst Pharmaceuticals's Unusual Options Activity ↗

August 16, 2021

BioCryst Pharmaceuticals (NASDAQ:BCRX) shares experienced unusual options activity on Monday. The stock price moved down to $15.44 following the option alert. Sentiment: BULLISH...

Via Benzinga

BioCryst Stock Jumps After Pulling Out $200M Equity Raise ↗

August 11, 2021

BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) has withdrawn its proposed public offering of $200 million of its stock and pre-funded warrants. The Company says...

Via Benzinga

The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering ↗

August 11, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.